EP Biocomposites Ltd

As of November 17, 2025, EP Biocomposites is fairly valued with a PE ratio of 15.35 and an EV to EBIT of 11.15, despite a year-to-date stock decline of 45.03%, contrasting with the Sensex's gain of 8.72%.

As of November 10, 2025, EP Biocomposites is considered overvalued with a valuation grade of expensive, reflected by a PE Ratio of 17.14 and a year-to-date stock return of -38.6%, significantly underperforming compared to the Sensex's 6.91% return.

EP Biocomposites has shown steady growth in net sales and profitability from Mar'21 to Mar'25, with net sales increasing from 2.95 Cr to 12.01 Cr and profit after tax rising from 0.36 Cr to 1.03 Cr, despite fluctuations in raw material costs and stagnant cash flow. Total assets and liabilities also grew significantly during this period.

The next results date for EP Biocomposites is November 3, 2025.

As of 27-Oct, EP Biocomposites Ltd's stock price is at 123.00, down 9.56%, underperforming its sector and the broader market significantly. The stock has seen a 28.07% decline year-to-date and a 53.02% drop over the past three years, indicating ongoing challenges.

As of 24-Oct, EP Biocomposites Ltd's stock price is at 136.00, reflecting an 8.8% increase. Despite a year-to-date decline of 20.47%, recent performance shows a positive shift with a 1-week return of 7.94%, outperforming the Sensex.

As of October 9, 2025, EP Biocomposites is considered very expensive and overvalued, with a PE ratio of 20.73, an EV to EBITDA of 12.76, and a Price to Book Value of 2.02, while its stock has underperformed the Sensex with a year-to-date return of -25.73%.

As of 08-Oct, EP Biocomposites Ltd is priced at 120.00 with no change, reflecting a significant decline of 6.21% in the past week and 29.82% year-to-date. Despite increased investor participation, the stock is trading below key moving averages and has underperformed compared to the broader market.

As of October 7, 2025, EP Biocomposites is considered overvalued with a valuation grade of expensive, a PE ratio of 19.59, and poor stock performance, reflected in a year-to-date return of -29.82%, contrasting with the Sensex's 4.85% return.

As of 30-Sep, EP Biocomposites Ltd is currently priced at Rs 127.95, reflecting an 8.0 point increase of 6.67%. Despite recent short-term gains, the stock has underperformed year-to-date, down 25.18%, amid declining investor participation and high volatility.

As of September 24, 2025, EP Biocomposites is considered overvalued with a PE ratio of 19.58 and an EV to EBITDA of 12.10, underperforming the Sensex with a year-to-date return of -29.85%.

As of 15-Sep, EP Biocomposites Ltd's stock price is Rs 119.95, down 2.52%, and has underperformed its sector. The stock has declined 9.81% over the past week and 29.85% year-to-date, trading below all major moving averages and showing erratic trading patterns.

As of 11-Sep, EP Biocomposites Ltd's stock price is at 123.05, down 8.75% today and 10.12% over the past week, with a year-to-date decline of 28.04%. The stock has underperformed compared to the benchmark Sensex, indicating weak investor confidence and challenges in attracting interest.

As of 10-Sep, EP Biocomposites Ltd's stock price is at 134.85, showing a 1.39% increase today. Despite recent short-term outperformance against the Sensex, the stock has underperformed year-to-date and over the past year, indicating volatility and declining investor confidence.

As of 05-Sep, EP Biocomposites Ltd's stock price is at 133.00, down 2.85%, with significant volatility and a year-to-date decline of 22.22%. The stock has underperformed its sector and the broader market, indicating challenges in attracting investor interest.

As of 04-Sep, EP Biocomposites Ltd is experiencing a price increase to Rs 136.90, up 7.54%, but has shown erratic trading and a significant decline in investor participation. Despite outperforming the sector recently, its long-term performance remains negative, with a year-to-date decline of -19.94%.

As of 01-Sep, EP Biocomposites Ltd's stock price is 127.30, reflecting a decline of 0.86%. The stock has underperformed significantly, with a year-to-date drop of 25.56% and a notable decrease in investor participation, indicating a troubling trend.

As of August 28, 2025, EP Biocomposites is considered undervalued with a valuation grade upgrade to very attractive, supported by a PE ratio of 20.96, an EV to EBIT of 13.25, and a ROCE of 16.54%, despite a challenging year with a YTD return of -24.91%.

As of 28-Aug, EP Biocomposites Ltd is experiencing a price increase to 128.40, up 7.0%, despite a year-to-date decline of 24.91%. The stock has shown erratic trading patterns and decreased investor participation, which may threaten future price stability.